Eiger BioPharmaceuticals Overview
- Year Founded
-
2008
- Status
-
Out of Business
- Employees
-
25
- Latest Deal Type
-
Out of Business
Eiger BioPharmaceuticals General Information
Description
Eiger BioPharmaceuticals Inc is a commercial stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare, and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria, and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3.
Contact Information
Website
www.eigerbio.comCorporate Office
- 2155 Park Boulevard
- Palo Alto, CA 94306
- United States
Corporate Office
- 2155 Park Boulevard
- Palo Alto, CA 94306
- United States
Eiger BioPharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Out of Business | 29-May-2025 | Completed | Out of Business | |||
| 8. Bankruptcy: Admin/Reorg | 01-Apr-2024 | Completed | Bankruptcy: Admin/Reorg | |||
| 7. Secondary Transaction - Open Market | Completed | Generating Revenue | ||||
| 6. Secondary Transaction - Open Market | Completed | Generating Revenue | ||||
| 5. Reverse Merger | 22-Mar-2016 | Completed | Generating Revenue | |||
| 4. Later Stage VC | Completed | Generating Revenue | ||||
| 3. Later Stage VC | 20-Nov-2015 | Completed | Generating Revenue | |||
| 2. Later Stage VC (Series A1) | 24-Mar-2015 | $14.5M | $22.8M | Completed | Generating Revenue | |
| 1. Early Stage VC (Series A) | 17-Sep-2010 | $8.3M | $8.3M | Completed | Startup |
Eiger BioPharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A1 | ||||||||
| Series A |
Eiger BioPharmaceuticals Comparisons
Industry
Financing
Details
Eiger BioPharmaceuticals Competitors (68)
One of Eiger BioPharmaceuticals’s 68 competitors is Zealand Pharma, a Formerly VC-backed company based in Soborg, Denmark.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Zealand Pharma | Formerly VC-backed | Soborg, Denmark | ||||
| Capricor Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| BioAtla | Formerly VC-backed | San Diego, CA | ||||
| Arbutus Biopharma | Corporation | Warminster, PA | ||||
| Lisata Therapeutics | Corporation | Basking Ridge, NJ |
Eiger BioPharmaceuticals Patents
Eiger BioPharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024123860-A1 | Methods to treat hepatitis delta viral infections | Inactive | 07-Dec-2022 | ||
| WO-2024123860-A9 | Methods to treat hepatitis delta viral infections | Inactive | 07-Dec-2022 | ||
| CA-3170254-A1 | Treatment of coronavirus infection with interferon lambda | Pending | 16-Mar-2022 | ||
| CA-3224859-A1 | Treatment of congenital hyperinsulinism with avexitide | Pending | 21-Jun-2021 | ||
| WO-2022271753-A1 | Treatment of congenital hyperinsulinism with avexitide | Inactive | 21-Jun-2021 | A61K38/26 |
Eiger BioPharmaceuticals Signals
Eiger BioPharmaceuticals Acquisitions (1)
Eiger BioPharmaceuticals’s most recent deal was a Merger/Acquisition with Celladon for . The deal was made on 22-Mar-2016.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Celladon | 22-Mar-2016 | Merger/Acquisition | Drug Discovery |
Eiger BioPharmaceuticals ESG
Risk Overview
Risk Rating
Updated December, 31, 2022
30.31 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,942
Rank
Percentile
Pharmaceuticals
Industry
of 914
Rank
Percentile
Biotechnology
Subindustry
of 412
Rank
Percentile
Eiger BioPharmaceuticals FAQs
-
When was Eiger BioPharmaceuticals founded?
Eiger BioPharmaceuticals was founded in 2008.
-
Where is Eiger BioPharmaceuticals headquartered?
Eiger BioPharmaceuticals is headquartered in Palo Alto, CA.
-
What is the size of Eiger BioPharmaceuticals?
Eiger BioPharmaceuticals has 25 total employees.
-
What industry is Eiger BioPharmaceuticals in?
Eiger BioPharmaceuticals’s primary industry is Drug Discovery.
-
Is Eiger BioPharmaceuticals a private or public company?
Eiger BioPharmaceuticals is a Private company.
-
What is Eiger BioPharmaceuticals’s current revenue?
The current revenue for Eiger BioPharmaceuticals is .
-
How much funding has Eiger BioPharmaceuticals raised over time?
Eiger BioPharmaceuticals has raised $39.5M.
-
Who are Eiger BioPharmaceuticals’s competitors?
Zealand Pharma, Capricor Therapeutics, BioAtla, Arbutus Biopharma, and Lisata Therapeutics are some of the 68 competitors of Eiger BioPharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process